January 14, 2025 • 1hr 21min

Tal Zaks - Bridging Science, Medicine, and Returns - [Invest Like the Best, EP.406]

Invest Like the Best with Patrick O'Shaughnessy

The episode features Tal Zaks, former Chief Medical Officer of Moderna during COVID-19 vaccine development and current biotech investor. His unique perspective combines deep medical expertise with platform technology experience and investing acumen. The conversation explores the intersection of scientific innovation, drug development, and venture returns while examining both the immense potential and significant challenges in advancing human health.

0:00

-0:00

Key Takeaways

Platform Innovation: MRNA and nucleic acid medicines represent a new "software-like" platform where the same physical construct can encode different information to create different drugs/vaccines
Investment Framework: Biotech investing requires balancing biology risk, pharmacology risk, and commercial potential - returns are typically 3-5x vs. 1000x in tech
COVID-19 Lessons: The rapid vaccine development showcased both the power of platform technologies and the importance of public trust/communication
Future of Medicine: AI and data collection will transform healthcare but human biology complexity means progress may be slower than pure technology fields
Healthcare System: Need to shift from "sick care" to preventive health while balancing innovation, returns, and ethical considerations

Introduction

The episode features Tal Zaks, former Chief Medical Officer of Moderna during COVID-19 vaccine development and current biotech investor. His unique perspective combines deep medical expertise with platform technology experience and investing acumen. The conversation explores the intersection of scientific innovation, drug development, and venture returns while examining both the immense potential and significant challenges in advancing human health.

Topics Discussed

Career Background and Current State of Medicine (07:04)

Tal describes his journey from physician-scientist through drug development, Moderna, and now investing. He sees medicine at an exciting but challenging junction:

Scientific advances are robust and promising
Translation to medicines remains highly unpredictable
Public perception and willingness to pay for innovation poses challenges
Return on investment is critical for continued innovation

Investment Philosophy in Therapeutics (22:58)

Tal outlines key considerations when evaluating biotech investments:

Team thesis and capability to execute
Capital requirements to reach value inflection points
Probability of success across multiple dimensions
Syndicate quality for long-term support
Personal ability to add value through experience

Platform Technologies and MRNA (53:54)

Discussion of nucleic acid medicines as transformative platforms:

Software-like nature where same physical construct carries different information
Marginal cost advantages after initial platform development
Potential for gene therapy and permanent genetic modifications
Ethical considerations around DNA modification

COVID-19 Vaccine Development (41:35)

Tal provides insider perspective on Moderna's COVID-19 vaccine development:

Platform readiness with 8/8 successful prior virus vaccines
Government partnership through Operation Warp Speed
Private capital funding for manufacturing scale-up
Unprecedented safety monitoring and data collection

Public Trust and Communication (50:38)

Reflections on public response to COVID-19 vaccines:

Need to balance scientific evidence with public autonomy
Science itself is not an ethical framework
Importance of open dialogue with public
Democratic process in health decisions

Future of Healthcare and Medicine (58:04)

Vision for evolution of healthcare:

Shift from "sick care" to preventive health
Increased data collection and personalization
AI integration while maintaining human element
Changed physician role as knowledge translators

AI Impact on Medicine (1:04:48)

Three scenarios for AI in healthcare:

Bear case: Slow progress in narrow verticals
Base case: Gradual integration with productivity gains
Bull case: System-wide transformation of care delivery
Limitations: Human biology complexity and ethical considerations

Investment Strategy in Therapeutics (1:08:34)

Key differences from tech investing:

Returns typically 3-5x vs 1000x in tech
Need higher success rate given lower upside
Multidisciplinary expertise required
Importance of asking right questions and finding trusted experts

The Human Element (1:14:57)

Discussion of human factors in medical innovation:

Balance of science and ethics
Importance of mentorship and paying it forward
Need for diverse perspectives
Value of clear communication across disciplines

Conclusion

The conversation highlights both the enormous potential and significant challenges in advancing human health through therapeutic innovation. Success requires carefully balancing multiple factors:

Scientific/technical innovation with practical implementation
Return on investment with public good
Speed of progress with safety/ethics
Data/AI capabilities with human factors

The future of medicine will likely be transformed by platform technologies, increased data collection, and AI integration - but progress may be more measured than pure technology fields due to biological complexity and ethical considerations. Successful investment in therapeutics requires understanding these nuances while maintaining focus on generating returns to drive continued innovation.